Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS, page-25

This is why you do your own fundamental analysis. The market has little idea about how to value biotech, but you can be rest easy that it will understand what fast track approval by the FDA for COVID-19 ARDS treatment means. Even Trump will be able to understand this.

There are so many posts here these days it is hard to keep up with all the great posts, but has there been much discussion around MSB going it alone for the COVID-19 ARDS indication? Normally you have to partner with a large pharma company to get access the doctors, but in this case MSB is going to be beating off all the requests for Remestemcel-L with a stick (assuming the trial goes well).

This might create a very interesting dynamic in that the only way for one of large pharma companies to get access is to launch an overwhelmingly high priced TO. This could happen out of the blue once informal data of how the current trial starts to leak - you can be sure that the large pharma companies will know before us how the trial is going given this trial is going to be very difficult to keep blinded.